Company intelligence / Profile preview
Leadermed Group
New York, New York, United Statesleadermedgroup.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Leadermed Group is advancing a pipeline of innovative therapeutics with a focus on Asia-Pacific markets. Its lead program, LM‑008—a novel GLP‑1 dual agonist—is entering Phase 3 trials in Indonesia to address high unmet needs in diabetes and obesity. The company has also licensed the ALT‑100 monoclonal antibody platform from Aqualung Therapeutics to target severe inflammatory disorders such as ARDS, with plans for multi-regional clinical trials. Additional programs include UltraSculpt, a device-based therapy for fat reduction and skin tightening. No published late-stage clinical results yet.
- Therapeutic areas
- PulmonologyEndocrinology
- Modalities
- Monoclonal antibody (e.g., ALT-100 mAb)Small molecule (implied by metabolic disease focus, e.g., diabetes/obesity drugs)Device (UltraSculpt body contouring treatment)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Combiphar (joint venture on LM–008 Phase 3 trial and commercialization in Indonesia)Aqualung Therapeutics Corporation [ALT–100 license agreement]
Beyond the preview
Go deeper on Leadermed Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Leadermed Group.